Estimating disease heritability from complex pedigrees allowing for ascertainment and covariates

Doug Speed^{1,*} and David M. Evans^{2,3,4}

¹ Center for Quantitative Genetics and Genomics, Aarhus University, Aarhus, Denmark

² Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia

³ Frazer Institute, University of Queensland, Brisbane, Australia

⁴ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK

* Corresponding author: doug@qgg.au.dk

We propose TetraHer, a method for estimating the liability heritability of binary phenotypes. TetraHer has five key features. Firstly, it can be applied to data from complex pedigrees, that contain multiple types of relationships. Secondly, it can correct for ascertainment of cases or controls. Thirdly, it can accommodate covariates. Fourthly, it can model the contribution of common environment. Fifthly, it produces a likelihood, that can be used for significance testing. We first demonstrate the validity of TetraHer on simulated data. We then use TetraHer to estimate liability heritability for 229 codes from the tenth International Classification of Diseases (ICD-10). We identify 118 codes with significant heritability (P<0.05/229), which can be used in future analyses for investigating the genetic architecture of human diseases.

INTRODUCTION

Estimates of heritability are of great value in statistical genetics. For example, they indicate the value of performing a genetic association study, and provide an upper bound for the accuracy of genetic prediction models.^{1,2} For a quantitative trait, heritability is defined as the proportion of phenotypic variation explained by genetic factors.³ For a binary phenotype, the same definition is referred to as heritability on the observed scale. An alternative is to assume a liability model, and then consider the proportion of liability variation explained by genetic factors, referred to as heritability on the liability scale.⁴ Most methods for estimating heritability were originally designed for quantitative traits. However, these methods are often applied to binary phenotypes via a two-step approach; first the method is used to estimate heritability on the observed scale, then this estimate is converted to the liability scale via a linear transformation.^{5,6}

In this paper, we focus on binary disease phenotypes, where each individual is recorded as either affected (a case) or unaffected (a control). When analyzing diseases, we generally prefer heritability estimates on the liability scale, because these do not depend on the prevalence and ascertainment of the disease, and can be readily compared across studies and traits.^{4,7}

We begin by using simulations to evaluate four existing methods for estimating liability heritability. The first two methods, Pearson's correlation and REML, use a two-step approach and tend to produce upwardly-biased estimates.^{3,8} The bias is highest for diseases with substantial heritability and low prevalence. For example, for diseases with prevalence 1%, the estimate can be more than twice the true value. We show that the bias arises because the linear transformation from the observed to liability scale fails for close relatives. The third method, PCGC, estimates liability heritability directly, but nonetheless exhibits biases similar to those of the two-step approaches.⁹ By contrast, the fourth method, tetrachoric correlation, estimates liability heritability directly and produces unbiased estimates.¹⁰

Our simulation results motivate us to develop TetraHer, which addresses five limitations of tetrachoric correlation. Firstly, TetraHer can be applied to complex pedigrees, where there are a mix of different relationships (including "non-standard" relationships inferred from SNP data). Secondly, TetraHer can correct for ascertainment, and thus produce more accurate estimates of liability heritability when cases or controls have been over-sampled. Thirdly, TetraHer can accommodate covariates. Fourthly, TetraHer can model the contribution of common environment. Fifthly, TetraHer reports a likelihood, which can be used to test whether the estimated heritability (or contribution of common environment) is significant.

We use TetraHer to estimate the heritability of 229 ICD-10 codes with prevalence at least 2% in the UK Biobank. We find that 118 of the codes have significant heritability (P<0.05/229), spanning 12 disease chapters. We then use these 118 codes to investigate the relationship between per-SNP heritability and minor allele frequency (MAF). All 13-15




Figure 1: Liability model and distribution of related pairs in the UK Biobank. (a) The liability model assumes that an individual's disease status indicates whether their liability (an unobserved, standard normally distributed random variable) is above (affected) or below (unaffected) a threshold (determined by the prevalence of the disease). (b) The distribution of SNP-derived estimates of relatedness for the 32,710 white British, related pairs in the UK Biobank.

METHODS

Here we summarize the methods and data used in this paper, with full details provided in **Supplementary Notes 1, 2 & 3.** Be aware that in the mathematical details, we use square brackets to specify elements of a vector or matrix (e.g., $a_1[b]$ denotes the bth element of a vector called a_1).

Notation. Suppose we have a sample of n individuals, and let the length-n vector Y record which are affected (Y[i]=1) and unaffected (Y[i]=0) for a particular disease. Let A=mean(Y[i]) denote the ascertainment of the disease (the proportion of cases in the sample), and let K denote the prevalence of the disease (the proportion of cases in the population). Further, suppose we have p covariates, whose values are contained within the n x p matrix Z. Throughout this paper, we assume a liability threshold model, as described in **Figure 1a**. If the length-n vector L denotes the (unobserved) liabilities of individuals, then Y[i]=I(L[i]>T), where $T=\Phi^{-1}(K)$ is the (1-K)th quantile of a standard normal distribution (e.g., if K=0.01, then Y[i] indicates whether or not L[i] is greater than 2.32).

Let R denote a symmetric n x n matrix such that R[i,j] records the genetic similarity between Individuals i and j. Traditionally, R contained coefficients of relatedness, the expected proportions of genome sharing, derived from pedigree information (e.g., full-siblings have R[i,j]=0.5, half-siblings have R[i,j]=0.25, etc). However, it is now common for R to contain SNP-derived estimates of relatedness, which measure the actual proportion of genome sharing (e.g., while full-siblings are expected to share half their genome, **Figure 1b** shows that the actual proportion shared typically ranges from 0.4 to 0.6). $^{16-18}$

Heritability definitions. When modeling variation in the observed phenotypes, we assume Y = F + G + C + E, where the independent, length-n vectors F, G, C and E denote the contributions of covariates, genetic factors, common environment and environmental noise, respectively. We then define heritability on the observed scale as $h^2_O = Var(G)/(Var(Y) - Var(F))$. When modeling variation in the liabilities, we instead assume L = F + G + C + E, and define heritability on the liability scale as $h^2_L = Var(G)/(Var(L) - Var(F))$. Most existing heritability methods are designed to estimate h^2_O . However, it has been argued that these estimates can be converted to the liability scale via the transformation

$$h_L^2 = h_O^2 \times \frac{K^2 (1 - K)^2}{A (1 - A) \phi(T)^2}$$
 Equation 1

where $\phi(T)$ is the density of a standard normal distribution evaluated at the threshold.^{4,6}

Note that the above definitions of h²_O and h²_L have been referred to as "conditional", because the denominators denote the variance of the phenotype or liability after allowing for covariates.⁹ An alternative is to consider the

"marginal" heritabilities Var(G)/Var(Y) and Var(G)/Var(L). We prefer conditional heritabilities, because in our opinion, heritability is ideally defined with respect to a homogeneous population, and therefore we consider the covariates nuisance parameters. However, for completeness, we also compute and report marginal heritabilities.

Analogous to the above definitions of heritability, we let $h^2_C = Var(C)/(Var(L)-Var(F))$ denote the proportion of liability variation explained by common environment.

Existing methods. We consider four existing methods for estimating liability heritability: Pearson's correlation and REML are two-step approaches (i.e., first obtain an estimate of h^2_O , then use Equation 1 to convert this to an estimate of h^2_L), while PCGC and Tetrachoric correlation estimate h^2_L directly.^{3,8–10} Here we briefly describe the four methods, and for simplicity, we ignore covariates (fuller descriptions are provided in **Supplementary Note 2**). Pearson's correlation estimates h^2_O based on ρ_P , the Pearson's correlation between phenotypes of related pairs (e.g., its estimate of h^2_O from full-siblings would be $2\rho_P$). REML estimates h^2_O by assuming Y \sim N(0, RVar(G) + IVar(E)), where I is an n x n identity matrix, then finds Var(G) and Var(E) that maximize the (restricted) likelihood. PCGC constructs Y', a standardized version of Y such that E(Y'[i]Y'[j]) \approx R[i,j] h^2_D , then estimates h^2_D by regressing the observed values of Y'[i]Y'[j] on R[i,j]. Tetrachoric correlation estimates h^2_D directly based on ρ_T , the tetrachoric correlation between phenotypes of related pairs (e.g., its estimate of h^2_D from full-siblings would be $2\rho_T$).

TetraHer. We first describe TetraHer assuming that the sample is not ascertained (i.e., A=K), and that there are no contributions from either covariates or common environment (i.e., F=0 and C=0); we then relax each of these conditions in turn. Suppose there are D related pairs (e.g., pairs with R[i,j]>0.05), and let the length-D vectors S_1 and S_2 index the first and second individuals in each pair, respectively. So for example, if Individuals 1 & 2 are related, we could set $S_1[i]=1$ and $S_2[i]=2$ (note that the order is arbitrary, so it is equivalent to instead set $S_1[i]=2$ and $S_2[i]=1$). In the following explanation, we use the vectors y_1 and y_2 to denote the phenotypes of the first and second individuals in each pair (i.e., $y_1=Y[S_1]$ and $y_2=Y[S_2]$), use the vectors l_1 and l_2 to denote their liabilities (i.e., $l_1=L[S_1]$ and $y_2=y[S_2]$), and use the vector r to denote their relatedness estimates (i.e., r[d] is the estimated relatedness between the dth pair).

TetraHer estimates h_L^2 by finding the value that maximizes the likelihood of the pairs of observed phenotypes. To construct a likelihood for the phenotype pair $(y_1[d], y_2[d])$, TetraHer assumes that the corresponding liability pair $(l_1[d], l_2[d])$ is a draw from a bivariate standard normal distribution with correlation $v[d]=r[d] h_L^2$. It is then possible to compute $P_{00}[d]$, $P_{10}[d]$, $P_{01}[d]$ and $P_{11}[d]$, the probabilities of observing the phenotype pairs (0,0), (1,0), (0,1) and (1,1), respectively. For example,

$$P_{00}[d] = \frac{1}{2\pi\sqrt{1-\nu[d]^2}} \int_{-\infty}^{T} \int_{-\infty}^{T} \exp\left(-\frac{a^2+b^2-2\nu[d]ab}{2(1-\nu[d]^2)}\right) da \, db$$

TetraHer computes a joint log likelihood by assuming the D pairs are independent

$$P(y_1,y_2|v) = \prod_d P_{y_1[d]y_2[d]}[d]$$

then estimates h_L^2 by maximizing the log likelihood using the Newton-Raphson Method. It estimates the variance of the estimate by inverting the second derivative of the log likelihood.

When the sample is ascertained (i.e., $A \neq K$), TetraHer revises how it computes the probabilities of observing the four different phenotype pairs. For example, it now computes

$$P_{\infty}[d] = \frac{1}{s[d]} \times \left(\frac{K(1-A)}{A(1-K)}\right)^{2} \times \frac{1}{2\pi\sqrt{1-v[d]^{2}}} \int_{-\infty}^{T} \int_{-\infty}^{T} \exp\left(-\frac{a^{2}+b^{2}-2v[d]ab}{2(1-v[d]^{2})}\right) da db$$

where the scalar s[d] ensures that $P_{00}[d]$, $P_{10}[d]$, $P_{01}[d]$ and $P_{11}[d]$ sum to one. The ratio (K(1-A))/(A(1-K)) is the relative probability that an unaffected individual is included in the sample (it will be less than one if A>K, and vice versa).

When allowing for covariates (i.e., $F\neq 0$), TetraHer starts by obtaining F', an estimate of F. Copying the approach of PCGC, TetraHer uses logistic regression to estimate the probabilities that individuals are affected given their covariates, then converts these to an estimate of F in a way that allows for ascertainment. ⁹ If f_1 and f_2 contain the covariates estimates for the first and second individuals in each pair (i.e., f_1 =F'[S_1] and f_2 =F'[S_2]), then TetraHer assumes that $l_1[d] - f_1[d]$ and $l_2[d] - f_2[d]$ are draws from a bivariate standard normal distribution with correlation r_d h^2 _L (i.e., replaces liabilities with their values after adjusting for covariates).

When allowing for common environment (i.e., $C\neq 0$), TetraHer assumes ($l_1[d]$ - $f_1[d]$, $l_2[d]$ - $f_2[d]$) is a draw from a bivariate standard normal distribution with correlation $v[d] = r[d] h^2_L + c[d] h^2_C$, where the length-D vector c describes the degree of common environment for the related pairs. Note that it is only possible to obtain (sensible) estimates of h^2_C when r and c are not linearly dependent.

In addition to TetraHer, we have also developed QuantHer, which is the analogous method for continuous phenotypes (e.g., when assuming no contributions from either covariates or common environment, QuantHer constructs a likelihood by assuming the phenotype pair $(y_1[d], y_2[d])$ is a draw from a bivariate normal distribution, with correlation $r[d] h^2_0$).

Relationship between TetraHer and tetrachoric correlation. We consider TetraHer a generalization of tetrachoric correlation. Specifically, **Supplementary Figure 1** shows that if we apply TetraHer to pairs of individuals with the same relationship (i.e., where $r_d=r_1$), and assume no ascertainment, nor contributions from either covariates or common environment (i.e., assume A=K, F=0 and C=0), then the resulting estimates of h_L^2 almost exactly equal ρ_T/r_1 (where we obtain ρ_T using the R package polycor^{19,20}).

Similarities between TetraHer and PCGC. TetraHer assumes the same model as PCGC, however, the two methods differ in their solvers.⁹ Instead of computing the probabilities $P_{00}[d]$, $P_{10}[d]$, $P_{01}[d]$ and $P_{11}[d]$ exactly, PCGC uses an approximation that relies on v[d] being small. PCGC is designed for analyzing unrelated pairs (e.g., r_d <0.05), in which case v[d] will tend to be very small, and the approximation is reasonable. However, when applied to related pairs, v[d] will often be substantial, and this approximation performs poorly (leading to the the biases observed below).

Similarities between TetraHer and structural equation modeling. In addition to the four existing methods described above, it is also possible to estimate liability heritability via structural equation modeling (SEM).²¹ In Supplementary Figure 2, we show that for the simplest analysis (i.e., when $r_d=r_1$, and assuming A=K, F=0 and C=0) estimates of h^2_L from SEM are almost identical to those from TetraHer. We believe that, in theory, many of the features of TetraHer are possible within SEM. However, we found that, despite trying alternative SEM software (e.g., lavaan,²² OpenMx²³ and sem²⁴), it was challenging to incorporate many of the features of TetraHer (e.g., allowing for complex pedigrees or ascertainment). We provide further comparison of TetraHer and SEM in the Discussion.

Data. In total, the UK Biobank contains approximately 487k individuals. ^{11,12} We first restrict to the 397,987 individuals who self-identified as white British, and whom we inferred to have European ancestry (via principal component analysis). We then used the software KING to infer family relationships. ²⁵ This identified 32,710 pairs of individuals within two degrees (142 identical twins, 18,176 full-siblings, 4,994 parent-child pairs, and 9,398 second-degree relatives), that span 56,602 unique individuals (**Figure 1b**). Each of these individuals is recorded for 23 covariates: age, sex, Townsend Deprivation Index and 20 principal components.

We first use the UK Biobank data for simulations (i.e., to generate phenotypes where we know the true heritability), then to estimate the heritability of diseases defined by ICD-10 codes (field 41270). In total, there are 19,133 ICD-10 codes, which are divided into 22 chapters (i.e., types of disease) and four levels (e.g., Level 3 codes are sub-categories of Level 2 codes). We restrict to the 229 codes in Chapters 1-15 with prevalence in the UK Biobank of at least 2%, of which 65, 90 and 74 are in Levels 1, 2 and 3, respectively. Note that for 37 of the codes, at least 80% of affected individuals were the same sex (females were predominantly affected for 29

codes, while males were predominantly affected for 8 codes), so for these we exclude individuals of the less-common sex in all analyses.

When running REML, PCGC and TetraHer, we set R based on the kinship estimates from KING (REML and PCGC require R_{ij} for all pairs of individuals, so we set R_{ij} =0 for pairs that King does not infer to be related). Pearson's correlation and Tetrachoric correlation can only be applied to pairs of individuals with the same relatedness. Therefore, we run each method twice for each phenotype, first using 23,170 pairs of full-siblings and parent-children (R_{ij} =0.5), then using 9,398 second-degree relatives (R_{ij} =0.25). We then combine the two estimates of h_L^2 into a single estimate via inverse-variance weighting.

Software. We make TetraHer available within our software package LDAK. Note that TetraHer is computationally efficient. For example, in the analyses below, we have approximately 30,000 pairs of related individuals, and TetraHer completes in seconds, and this remains the case even with 100,000s of related pairs. Furthermore, we have designed TetraHer so it is easy to use. In particular, all analyses in this paper can be performed using a one-line command, and we have ensured that, when possible, the TetraHer syntax matches that used by the popular software PLINK (for example, phenotypes and covariates are specified using the flags—pheno and—covar, respectively). We provide full instructions for running TetraHer (including test datasets) on the LDAK website, with a summary in **Supplementary Note 4**.

RESULTS

Advantage of tetrachoric correlation and TetraHer over two-step methods. First we simulate diseases with prevalence 1%, 10% or 50%, with h_L^2 equal to 0.2, 0.5 or 0.8, with no ascertainment, nor contributions from either covariates or common environment. **Figure 2a, 2b & 2c** show that estimates of h_L^2 from Pearson's correlation, REML and PCGC are upwardly biased, with the extent of the bias depending on the heritability and prevalence. For example, for traits with prevalence 1% and heritability 0.5 or 0.8, the average estimate of h_L^2 is over twice the true value. By contrast, tetrachoric correlation and TetraHer produce consistent estimates of h_L^2 .

For the above simulations, the diseases are moderately polygenic (1000 causal SNPs), and effect sizes are sampled such that causal SNPs with lower MAF tend to explain less phenotypic variation (a tendency observed for real human traits).²⁷ However, **Supplementary Figures 3 & 4** show that the results are almost identical if we instead consider highly polygenic diseases (20,000 causal SNPs) or generate effect sizes so that all causal SNPs are expected to explain equal phenotypic variation.




Figure 2: Comparison of methods for estimating heritability of simulated phenotypes. For (a), (b) and (c), we simulate disease phenotypes with prevalence 1%, 10% and 50%, respectively, then estimate liability heritability, h_L^2 , using Pearson's correlation, REML, PCGC, Tetrachoric correlation and TetraHer; for (d), we simulate quantitative phenotypes, then estimate observed heritability, h_0^2 , using Pearson's correlation, REML, Haseman-Elston regression and QuantHer. Boxes report estimates across 50 replicates (horizontal lines mark the 25th, 50th and 75th percentiles). Dashed horizontal lines indicate the true heritability (0.2, 0.5 or 0.8, depending on phenotype).

Figure 2d show that when applied to simulated quantitative traits, Pearson's correlation, REML and Haseman-Elston regression²⁸ (the equivalent of PCGC for quantitative traits) produce unbiased estimates of h_0^2 . This indicates that the inflation observed for binary phenotypes occurs when converting heritability estimates from the observed to liability scale.¹⁰ **Figure 3** shows that the inflation arises because Equation 1 is only a good approximation when the correlations between pairwise liabilities (equal to r[d] h_L^2 +c[d] h_C^2) tend to be small, or when the prevalence of the disease is close to 50%.

Advantages of TetraHer over tetrachoric correlation. TetraHer is able to analyze all pairs of individuals together, whereas tetrachoric correlation can only analyze pairs with the same relatedness. This is primarily a convenience (i.e., TetraHer can analyze all data in a single analysis, instead of multiple, and it can accommodate non-standard estimates of relatedness). However this feature also leads to a slight increase in precision. For example, **Figure 4a** shows that for diseases with h^2_L =0.5 and prevalence 1%, estimates from TetraHer have standard deviations on average 10% smaller than those from tetrachoric correlation.




Figure 3. Relationship between correlations on the observed and liability scales. We generate pairs of liabilities with correlations ranging from 0.05 to 0.4, then convert these to pairs of binary phenotypes with prevalences between 1% and 50%. The points show how the correlation between the binary phenotypes (y-axis) depends on the correlation between the corresponding liabilities (x-axis) and the prevalence, while the lines show the relationship predicted by Equation 1.

For **Figure 4b**, we introduce ascertainment, by either over-sampling or under-sampling cases. TetraHer can allow for ascertainment, and so continues to produce accurate estimates of h_L^2 . By contrast, tetrachoric correlation does not allow for ascertainment, and as a result tends to overestimate h_L^2 when cases are over-sampled and underestimate h_L^2 when cases are under-sampled. For **Figure 4c** we simulate phenotypes where the covariate age explains either 5 or 20% of liability variation. TetraHer is able to accommodate covariates, and therefore continues to produce accurate estimates of h_L^2 . By contrast, tetrachoric correlation can not include covariates, and as a result tends to underestimate h_L^2 .

For **Figure 4d**, we simulate phenotypes where 20% of variation in liability is due to common environment (for this we consider the simple case where c[d]=1 for all d, which corresponds to the assumption that all related pairs share a common environment). TetraHer can model this contribution, and therefore continues to produce accurate estimates of h_L^2 . By contrast, tetrachoric correlation can not model the contribution of common environment, and as a result tends to overestimate h_L^2 .

The fifth advantage of TetraHer over tetrachoric correlation is that it reports a likelihood, which can be used to perform likelihood ratio tests (i.e., to test whether a trait has significant h²_L and/or h²_C). **Supplementary Figure** 5 indicates that this likelihood is well-calibrated under the null hypothesis.




Figure 4: Comparison of tetrachoric correlation and TetraHer on simulated diseases. (a) We first simulate disease phenotypes with $h_L^2=0.5$ and prevalence 1%, 10% or 50%. Points compare the standard deviation of estimates of h_L^2 from tetrachoric correlation and TetraHer. We then modify the phenotypes in three ways: (b) so that the proportion of cases in the sample no longer matches the disease prevalence, (c) so that the covariate age explains either 5% of 20% of liability variation, (d) so that common environment explains either 0% or 20% of liability variation. Boxes report estimates of h_L^2 across 50 replicates (horizontal lines mark the 25th, 50th and 75th percentiles).

Heritability of ICD-10 phenotypes. Table 1 and Supplementary Table 1 report estimates of h_L^2 for the 229 ICD-10 codes. For these estimates, we assume there is no ascertainment (i.e., that the prevalence in the UK Biobank sample matches the population prevalence), we include covariates (in general, all 23 covariates, however, when analyzing the 37 single-sex codes, we exclude sex) and assume there is no contribution from common environment. 118 of the codes have significant heritability (P<0.05/229 from a likelihood ratio test). These 118 codes span 12 chapters, with 35, 48 and 35 in Levels 1, 2 and 3, respectively (Supplementary Figure 6). Instructions on how to construct these phenotypes for UK Biobank individuals are provided on the LDAK website with a summary in Supplementary Note 5.

Code	Description	Sex	Prevalence	Estimate of h ² _L	SD
C44	Other malignant neoplasms of skin	Both	0.047	0.409	0.050
C50	Malignant neoplasm of breast	Females	0.063	0.413	0.069
C61	Malignant neoplasm of prostate	Males	0.057	0.584	0.097
D12	Benign neoplasm of colon, rectum, anus and anal canal	Both	0.055	0.313	0.047
D25	Leiomyoma of uterus	Females	0.051	0.311	0.078
D50	Iron deficiency anaemia	Both	0.037	0.263	0.057
E03	Other hypothyroidism	Both	0.054	0.447	0.045
E11	Non-insulin-dependent diabetes mellitus	Both	0.069	0.630	0.040
E66	Obesity	Both	0.062	0.415	0.043
E78	Disorders of lipoprotein metabolism and other lipidaemias	Both	0.138	0.351	0.031
F17	Mental and behavioural disorders due to use of tobacco	Both	0.045	0.312	0.051
F32	Depressive episode	Both	0.054	0.265	0.048
F41	Other anxiety disorders	Both	0.038	0.322	0.058
G47	Sleep disorders	Both	0.021	0.360	0.089
G56	Mononeuropathies of upper limb	Both	0.033	0.361	0.058
H25	Senile cataract	Both	0.053	0.283	0.051
H26	Other cataract	Both	0.070	0.324	0.048
H40	Glaucoma	Both	0.024	0.652	0.069
I10	Essential (primary) hypertension	Both	0.278	0.406	0.023
I20	Angina pectoris	Both	0.059	0.328	0.048
I25	Chronic ischaemic heart disease	Both	0.090	0.383	0.040
I48	Atrial fibrillation and flutter	Both	0.068	0.433	0.045
I50	Heart failure	Both	0.029	0.332	0.074
I83	Varicose veins of lower extremities	Both	0.033	0.424	0.057
J18	Pneumonia, organism unspecified	Both	0.048	0.226	0.055
J44	Other chronic obstructive pulmonary disease	Both	0.039	0.445	0.060
J45	Asthma	Both	0.088	0.361	0.035
K20	Oesophagitis	Both	0.030	0.275	0.063
K21	Gastro-oesophageal reflux disease	Both	0.099	0.206	0.034
K22	Other diseases of oesophagus	Both	0.038	0.253	0.059
K29	Gastritis and duodenitis	Both	0.102	0.200	0.034
K40	Inguinal hernia	Males	0.104	0.319	0.073
	Diaphragmatic hernia	Both	0.099	0.202	0.035
	Diverticular disease of intestine	Both	0.119	0.329	0.032
K63	Other diseases of intestine	Both	0.063	0.268	0.044
K80	Cholelithiasis	Both	0.050	0.248	0.049
	Coxarthrosis [arthrosis of hip]	Both	0.048	0.287	0.054
	Gonarthrosis [arthrosis of knee]	Both	0.074	0.369	0.040
	Other arthrosis	Both	0.080	0.260	0.039
M20	Acquired deformities of fingers and toes	Females	0.045	0.398	0.083
	Internal derangement of knee	Both	0.043	0.243	0.056
	Spondylosis	Both	0.035	0.251	0.062
	Other spondylopathies	Both	0.020	0.344	0.087
	Other intervertebral disk disorders	Both	0.028	0.326	0.068
	Dorsalgia	Both	0.057	0.236	0.047
	Other soft tissue disorders, not elsewhere classified	Both	0.048	0.254	0.053
	Hyperplasia of prostate	Males	0.105	0.471	0.079
	Female genital prolapse	Females	0.065	0.271	0.070
	O r r			- · · -	· -

Table 1: Significant Level 2 ICD-10 codes. We applied TetraHer to 229 ICD-10 codes, assuming no ascertainment, including 23 covariates, and assuming no contribution from common environment. In total, we identified 118 codes with significant h_L^2 (P < 0.05/229); this table details the 48 significant Level 2 codes.




Figure 5: Sensitivity analyses of 229 ICD-10 codes. Our main analysis of the ICD-10 codes assumed no ascertainment, included 23 covariates, and assumed no contribution from common environment. (a) We repeat the analysis assuming the population prevalence is twice the observed prevalence; points compare revised and original estimates of h_L^2 . (b) Same as (a), except now points compare revised and original -log10 p-values from testing whether $h_L^2=0$ (note that values above 15 have been truncated). (c) We repeat the analysis excluding covariates; points compare revised and original estimates of h_L^2 . (d) We repeat the analysis allowing for common environment; points report -log10 p-values from testing whether $h_C^2=0$. In all panels, red points mark the 118 codes with significant heritability (P<0.05/229) from the original analysis, while horizontal and vertical lines correspond to P=0.05/229.

We perform three sensitivity analyses. Firstly, we repeat the analysis assuming the population prevalence is twice the sample prevalence, to allow for possible ascertainment due to "healthy volunteer bias". **Figure 5a** shows that the revised estimates of h_L^2 are on average 11% higher than the original ones, while **Figure 5b** shows there is limited change to which codes have significant heritability (three codes change from significant to non-significant, while two change from non-significant to significant). Secondly, we repeat the analysis excluding covariates. **Figure 5c** shows that the revised estimates of h_L^2 are similar to the original ones, reflecting that the covariates tend to explain only a small proportion of liability variation (mean 8%, median 6%). Thirdly, we repeat the analysis allowing for the contribution of common environment. **Figure 5d** shows that there is no significant contribution from common environment for any of the 229 codes (the smallest p-value is 0.002, which is not significant after correction for multiple testing).




Figure 6: Relationship between per-SNP heritability and MAF. We model the relationship via the power parameter α (see main text). Points report estimates of α for the 118 ICD-10 codes with significant heritability. The disease chapter is indicated by the point shape and color. The top horizontal solid line marks the inverse-variance weighted average across all codes, while the bottom horizontal solid line reports the estimate of α for height (dashed horizontal lines provide the corresponding 95% confidence intervals).

By way of comparison, we also analyze the quantitative trait height (using QuantHer). As shown in **Supplementary Table 2**, we find a substantial contribution from covariates (in total, they explain 54% of phenotypic variation, primarily driven by sex, and ignoring them reduces the estimate of h^2_{C} from 0.83 to 0.63). We also find a significant contribution from common environment (the estimate of h^2_{C} is 0.10, with the likelihood ratio test P<1e-16).

Relationship between per-SNP heritability and MAF. We hope the 118 significantly heritable ICD-10 codes will be a useful resource for investigating the genetic architecture of human diseases. To provide an example, we use SNP-based heritability analysis to infer the relationship between per-SNP heritability and MAF. ^{13–15} Specifically, we use our software SumHer to estimate the power parameter α in the model $E[h_j^2] \propto [p_j(1-p_j)]^{1+\alpha}$ where $E[h_j^2]$ is the expected heritability contributed by SNP j, and p_j is its MAF. ^{15,29} **Figure 6** and **Supplementary Table 3** report estimates of α for the 118 ICD-10 codes. The inverse-variance weighted average estimate across all codes is -0.23 (SD 0.02), and this does not change much if we instead restrict to the 35 Level 1 codes (estimate -0 .19, SD 0.04), the 48 Level 2 codes (estimate -0 .24, SD 0.03) or the 35 Level 3 codes (estimate -0 .26, SD 0.04). While negative α indicates that rarer causal variants tend to have a larger effect size than more common causal variants, consistent with the action of negative selection, we note

that the average estimate is higher than that for height (estimate -0.49, SD 0.01). Further, we find only weak evidence that α varies with disease prevalence (weighted least-squares regression slope 0.50, p-value 0.06).

DISCUSSION

We have developed TetraHer, a method for estimating liability heritability of binary phenotypes which has five key features: it can be applied to complex pedigrees, it allows for ascertainment, it accommodates covariates, it can model the contribution of common environment, and it produces a likelihood.

We first used simulated data to test the validity of TetraHer. We recognize that in our simulations, we had the benefit of knowing the truth, and thus we were able to run TetraHer optimally. In particular, when simulating ascertained phenotypes, we knew the true disease prevalence, while when simulating phenotypes where covariates (common environment) explained liability variation, we knew which covariates to include (the degree of environmental similarity between related pairs). For analyses of real phenotypes, these details are often not available. For example, when analyzing real disease, it can be hard to estimate the population prevalence, while if substantial liability variation is explained by a covariate that is not recorded, TetraHer will be unable to adjust for its contribution.

We additionally used the simulated data to demonstrate the advantage of TetraHer over four existing methods, Pearson's correlation, PCGC, REML and tetrachoric correlation. We also briefly considered SEM, showing that for the simplest analysis (i.e., where there is only one type of relationship, and ignoring ascertainment, covariates and common environment), estimates from SEM were almost identical to those TetraHer. We recognize that our comparison with SEM was far from comprehensive. This is because there are many implementations of SEM, most of which allow the user to specify a wide variety of models and choose from a range of solvers. In particular, while it is theoretically possible to implement all five features of Tetraher within an SEM framework, doing so would be complicated and require the user to have specialist knowledge. Moreover, we believe that the resulting analyses would be much slower than TetraHer (which always completed within five seconds, even for the most advanced analyses).

We subsequently used TetraHer to identify heritable ICD-10 codes based on UK Biobank data. This analysis demonstrated the advantage of being able to allow for ascertainment, as we could then investigate the potential impact of healthy volunteer bias. Due to the large number of codes analyzed, and the difficulty of finding prevalence estimates for ICD-10 codes, we considered only two scenarios for each code: A=K (i.e., no ascertainment) and K/A=2 (i.e., that the population prevalence was double the sample prevalence). The latter was motivated by a previous study that estimated K/A for four ICD-10 codes with sample prevalence >2%

(their estimates were 1.8, 1.8, 2.3 and 2.4), and we consider this a reasonable upper bound for K/A.³⁰ While we believe this assumption sufficed in terms of demonstrating estimates are reasonably robust to ascertainment caused by healthy volunteer bias, we recognize that more accurate estimates of h²_L could be obtained by finding individual estimates of prevalence for each code.

We found that when applying TetraHer to the ICD-10 codes, there was limited advantage including covariates or modeling the contribution of common environment (because neither were estimated to explain a substantial proportion of liability variation). Nonetheless, there are many phenotypes where these two features would be more beneficial (our analysis of height provided one example). Moreover, we expect TetraHer to be advantageous when applied to datasets where inbreeding is common (e.g., for animal and plant datasets), as then there will be a wider spectrum of relatedness values, and therefore a larger benefit being able to use actual relatedness instead of expected relatedness.

We have identified 118 heritable ICD-10 codes, spanning a wide range of disease types, that will be a useful resource for better understanding human diseases. We have provided one example of how this information can be used (to examine the relationship between per-SNP heritability and MAF). However, there are a wide range of other possible applications, such as inferring the number of causal variants, identifying enriched pathways, measuring the performance of prediction models, and estimating genetic correlation between diseases.

ACKNOWLEDGMENTS

D.S. is supported by the Aarhus University Research Foundation (AUFF) and by the Independent Research Fund Denmark (project no. 7025-00094B). D.M.E. is supported by an NHMRC Investigator Grant (application ID 2017942).

WEB RESOURCES

LDAK, https://www.dougspeed.com

TetraHer documentation, https://www.dougspeed.com/tetraher

Instructions for obtaining the 118 significant ICD10 codes, https://www.dougspeed.com/icd10

REFERENCES

1. Visscher, P. M., Brown, M. a., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. *Am. J. Hum. Genet.* **90**, 7–24 (2012).

- 2. Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of complex traits from individual-level data or summary statistics. *Nat. Commun.* **12**, 1–9 (2021).
- 3. Falconer, D. & Mackay, T. *Introduction to Quantitative Genetics (4th Edition)*. (Longman, 1996).
- 4. Dempster, E. & Lerner, I. Heritability of threshold characters. *Genetics* **35**, 212–236 (1950).
- 5. Robertson, a. & Lerner, I. M. The heritability of all-or-none traits; viability of poultry. *Genetics* **34**, 395–411 (1949).
- 6. Lee, S., Wray, N., Goddard, M. & Visscher, P. Estimating missing heritability for disease from genomewide association studies. *Am. J. Hum. Genet.* **88**, 294–305 (2011).
- 7. Witte, J. S., Visscher, P. M. & Wray, N. R. The contribution of genetic variants to disease depends on the ruler. *Nat. Rev. Genet.* **15**, 765–776 (2014).
- 8. Corbeil, R. R. & Searle, S. R. Restricted maximum likelihood (REML) estimation of variance components in the mixed model. *Technometrics* **18**, 31–38 (1976).
- 9. Golan, D., Lander, E. S. & Rosset, S. Measuring missing heritability: Inferring the contribution of common variants. *Proc. Natl. Acad. Sci.* **111**, E5272–E5281 (2014).
- 10. Tenesa, A. & Haley, C. The heritability of human disease: estimation, uses and abuses. *Nat. Rev. Genet.* **14**, 139–149 (2013).
- 11. Sudlow, C. *et al*. The UK Biobank resource with deep phenotyping and genomic data. *PLoS Med.* **12**, e1001779 (2015).
- 12. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. (2018) doi:10.1038/s41586-018-0579-z.
- 13. Schoech, A. et al. Quantification of frequency-dependent genetic architectures and action of negative selection in 25 {UK} {B}iobank traits. (2017).
- 14. Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex traits. *Nat Genet* **50**, 746–753 (2018).
- 15. Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models using summary statistics. *Nat. Genet.* **52**, 458–462 (2020).
- 16. Visscher, P. M. *et al.* Assumption-free estimation of heritability from genome-wide identity-by-descent sharing between full siblings. *PLoS Genet* **2**, e41 (2006).
- 17. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat. Genet.* **42**, 565–569 (2010).
- 18. Speed, D., Hemani, G., Johnson, M. R. & Balding, D. J. Improved heritability estimation from genomewide SNPs. *Am. J. Hum. Genet.* **91**, 1011–21 (2012).
- 19. Fox, J. polycor: Polychoric and Polyserial Correlations. (2022).
- 20. R Core Team. R: A Language and Environment for Statistical Computing. (2023).

- 21. Neale, M. C., Eaves, L. J. & Kendler, K. S. The power of the classical twin study to resolve variation in threshold traits. *Behav. Genet.* **24**, 239–258 (1994).
- 22. Rosseel, Y. Quantitative aspects of blood flow and oxygen uptake in the human forearm during rhythmic exercise. *J. Stat. Softw.* **48**, (2012).
- 23. Neale, M. C. *et al.* OpenMx 2.0: Extended Structural Equation and Statistical Modeling. *Psychometrika* **81**, 535–549 (2016).
- 24. Fox, J. Structural equation modeling with the sem package in R. *Struct. Equ. Model.* **13**, 465–486 (2006).
- 25. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867–2873 (2010).
- 26. Chang, C. C. *et al.* Second-generation PLINK: Rising to the challenge of larger and richer datasets. *Gigascience* **4**, 1–16 (2015).
- 27. Speed, D., Cai, N., Johnson, M. R., Nejentsev, S. & Balding, D. J. Reevaluation of SNP heritability in complex human traits. *Nat. Genet.* **49**, 986–992 (2017).
- 28. Haseman, J. & Elston, R. The investigation of linkage between a quantitative trait and a marker locus. *Behav. Genet.* **2**, 3–19 (1972).
- 29. Speed, D. & Balding, D. SumHer better estimates the SNP heritability of complex traits from summary statistics. *Nat. Genet.* **51**, 277–284 (2019).
- 30. Ojavee, S. E., Kutalik, Z. & Robinson, M. R. Liability-scale heritability estimation for biobank studies of low-prevalence disease. *Am. J. Hum. Genet.* **109**, 2009–2017 (2022).